Cosmo Pharmaceuticals N.V.
COPN.SW News Today: Stay Updated with the Latest Cosmo Pharmaceuticals N.V. News in Real Time
Find COPN.SW news now at Meyka AI. Stay informed with the latest Cosmo Pharmaceuticals N.V. stocks updates, including price news, market analysis, and expert insights.
PHASQ falls 99.00% to $0.000001 on 03 Apr 2026: immediate liquidity risk
PHASQ stock fell 99.00% to $0.000001 on 03 Apr 2026; Meyka AI explains drivers, liquidity, and forecast for investors
^GSPC Today April 03: Pharma 100% Tariff, Metals Duty Overhaul
Trump tariffs shake markets as pharma faces a 100% headline rate and metals duties tighten to spot prices. What this means for HK investors and the S&P 500 today.
CSCI.TO COSCIENS Biopharma (TSX) up 90.08% intraday 02 Apr 2026: catalyst, outlook
Intraday: CSCI.TO stock jumps 90.08% to C$2.30 on 02 Apr 2026; volume surge and Meyka forecast analysis
Australia stocks lower at close of trade; S&P/ASX 200 falls 1.06% amid market weakness
Australia stocks ended significantly lower at the close of trade on April 2, 2026, as the benchmark S&P/ASX 200 fell 1.06 percent to 8,579.50 points, reflecting a broad market sell‑off driven by geopolitical risk, rising oil prices, and weaker investor sentiment across major sectors. The drop marked a clear reversal from the prior session’s strong…
Aurobindo Pharma, Biocon, Glenmark Shares Plunge Over 5% as Nifty Pharma Drops 3.5%
The Indian stock market witnessed heavy selling in pharmaceutical companies as sectoral weakness dragged major stocks lower. Shares of Aurobindo Pharma, Biocon, and Glenmark Pharmaceuticals declined more than 5%, while the Nifty Pharma index dropped nearly 3.5%, emerging as one of the worst-performing sectoral indices of the session. The broad-based fall reflected global concerns, tariff…
RMB23.4bn loss at Fosun (0656.HK HKSE) pre-mkt Apr 2026: watch pharma recovery
Pre-market Apr 2026: 0656.HK stock — RMB23.4bn loss, core pharma growth; Meyka AI year target HKD 4.82 (+12.58%)
ADMS Adamas Pharma NASDAQ Apr 2026 Pre-Mkt $8.22: Oversold bounce 10.7% upside
Pre-market ADMS stock at $8.22 shows an oversold bounce setup with 10.7% short-term upside per Meyka AI forecast
Biogen to Buy Apellis in $5.6 Billion All‑Cash Deal
Biotech giant Biogen announced a major deal to acquire Apellis Pharmaceuticals for $5.6 billion in cash, marking one of the largest strategic transactions in the sector this year. The acquisition is aimed at strengthening Biogen’s drug pipeline, especially in areas such as eye disease and immunology where Apellis has developed promising therapies. Investors reacted strongly…
Centessa Shares Soar Following Lilly’s $6.3B Acquisition Announcement
The stock market reacted strongly after a major acquisition announcement involving Centessa Shares. Eli Lilly, one of the largest pharmaceutical companies in the world, confirmed it will acquire Centessa Pharmaceuticals for $6.3 billion in an all‑cash deal. This news caused Centessa Shares to surge sharply, making the acquisition one of the most talked‑about deals in…